#SFHS2609407AFrance expands public reimbursement for OLUMIANT in certain juvenile arthritis cases
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This measure expands public coverage in France for OLUMIANT 2 mg and 4 mg tablets for children aged 2 and older with certain forms of juvenile idiopathic arthritis, including polyarticular disease, extended oligoarticular arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis. The coverage applies when patients have not responded well to, or cannot tolerate, one or more disease-modifying treatments, including at least one anti-TNF drug when possible. The practical effect is that hospitals, public services, and prescribers can now use these products under the public approved list for these broader pediatric indications. Lilly France and healthcare providers treating eligible children are directly affected, while payers and procurement teams need to apply the updated reimbursement rules.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Public coverage is expanded for OLUMIANT 2 mg and 4 mg tablets in France.
- The new coverage covers several juvenile idiopathic arthritis indications in patients aged 2 and older.
- The approved use applies after inadequate response or intolerance to DMARDs, including at least one anti-TNF when possible.
Obligations
What this law requires
Public healthcare bodies, collectors, and other public services in France may include OLUMIANT 2 mg and OLUMIANT 4 mg tablets on the approved list for public use for children aged 2 years and older with juvenile idiopathic arthritis subtypes specified in the annex, provided the patient has had an inadequate response or intolerance to one or more DMARDs, including at least one anti-TNF when possible.
Healthcare providers treating eligible pediatric patients must apply the expanded public coverage criteria in the annex when determining access to OLUMIANT for polyarticular juvenile idiopathic arthritis, extended oligoarticular arthritis, enthesitis-related arthritis, and juvenile psoriatic arthritis.
Payers and procurement teams must treat OLUMIANT 2 mg and 4 mg tablets as covered public-use specialties for the expanded pediatric indications listed in the annex when reimbursement and purchasing decisions are made.
The official list of pharmaceutical specialties approved for use by public institutions and services is amended in accordance with the annex, so public-sector users must rely on the updated list rather than the prior coverage scope.
Lilly France SAS must ensure the identified product presentations remain accurately identified as covered specialties under the French public approval list for the annexed indication extension.